The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia

References

• World Health Organization (WHO). Schizophrenia 2018 [Internet] [cited 2018 Jun 22]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/schizophrenia
   Google Scholar
• National Institute of Mental Health (NIMH). Schizophrenia 2018 [Internet] [cited 2018 Aug 7]. 2018. Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml
   Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44:1195–1203.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health (UK). Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014. (NICE Clinical Guidelines, No. 178.) 2, Psychosis and Schizophrenia in Adults [Internet]. London: National Institute for Health and Care Excellence (UK); 2014. [cited 2018 Aug 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK333029/
   Google Scholar
• Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50. doi: 10.1186/1471-244X-13-50.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56.
   PubMed Web of Science ®Google Scholar
• Gopal S, Xu H, McQuarrie K, et al. Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. NPJ Schizophren. 2017;3(1):23. doi: 10.1038/s41537-017-0025-5.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66(9):1122-1129. PubMed PMID: 16187769; eng.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764-771. doi: 10.4088/JCP.15m10278. PubMed PMID: 27135986; eng.
   PubMed Web of Science ®Google Scholar
• Huang A, Amos TB, Joshi K, et al. Understanding healthcare burden and treatment patterns among young adults with schizophrenia. J Med Econ. 2018;27:1-10. doi: 10.1080/13696998.2018.1500370.
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington VA: American Psychiatric Publishing; 2013. 2013. p. 102.
   Google Scholar
• Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;30(3):286-297. doi: 10.1007/s12325-013-0016-5.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures. 2014;5:43-62. doi: 10.2147/PROM.S42735.
   Google Scholar
• Anderson JP, Icten Z, Alas V, et al. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry. 2017;17:346. doi: 10.1186/s12888-017-1507-8.
   PubMed Web of Science ®Google Scholar
• Joshi K, Lafeuille MH, Kamstra R, et al. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. J Comp Eff Res. 2018;7(2):121-133. doi: 10.2217/cer-2017-0043.
   PubMed Web of Science ®Google Scholar
• Pilon D, Tandon N, Lafeuille MH, et al. Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clin Ther. 2017;39(10):1972-1985.e2. doi: 10.1016/j.clinthera.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Pilon D, Joshi K, Tandon N, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619-629. doi: 10.2147/ppa.s127623.
   PubMed Web of Science ®Google Scholar
• Pilon D, Muser E, Lefebvre P, et al. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry. 2017;17(1):207. doi: 10.1186/s12888-017-1358-3.
   PubMed Web of Science ®Google Scholar
• Pilon D, Joshi K, Kamstra R, et al., editors. Quality measure attainment among adults diagnosed with schizophrenia treated with paliperidone palmitate. National Harbor, MD: AMCP Nexus; 2016.
   Google Scholar
• Lang K, Meyers JL, Korn JR, et al. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010;61(12):1239-1247. doi: 10.1176/ps.2010.61.12.1239.
   PubMed Web of Science ®Google Scholar
• Panish J, Karve S, Candrilli SD, et al. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. J Pharm Health Serv Res. 2013;4(1):29-39. doi: 10.1111/jphs.12004.
   PubMedGoogle Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891. doi: 10.1176/appi.ps.55.8.886.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453-460.
   PubMed Web of Science ®Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161(4):692-699. doi: 10.1176/appi.ajp.161.4.692.
   Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630-639. doi: 10.1097/01.mlr.0000021003.43524.64.
   PubMed Web of Science ®Google Scholar
• Medic G, Higashi K, Littlewood KJ, et al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2013;9:119-131. doi: 10.2147/ndt.s39303.
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200-218. doi: 10.1177/2045125312474019.
   PubMedGoogle Scholar
• Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry. 2009;195(S52):s63-s67. doi: 10.1192/bjp.195.52.s63.
   Web of Science ®Google Scholar
• The University of South Florida; Florida Medicaid Drug Therapy Management Program sponsored by the Florida Agency for Health Care Administration. 2017–2018 Florida Best Practice Psychotherapeutic Medication Guidelines for Adults 2018 [Internet] [cited 2018 Aug 27]. 2018. Available from: https://medicaidmentalhealth.fmhi.usf.edu/_assets/file/Guidelines/2018-Psychotherapeutic%20Medication%20Guidelines%20for%20Adults%20with%20References.pdf
   Google Scholar
• Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-299.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Invega Sustenna (paliperidone palmitate) Prescribing Information [Internet] [cited 2017 Dec]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022264s015lbl.pdf
   Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. doi: 10.4088/JCP.14m09584.
   Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171-1180. doi: 10.2147/PPA.S53795.
   PubMed Web of Science ®Google Scholar
• Bera R, Offord S, Zubek D, et al. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ. 2013;16(4):522-528. doi: 10.3111/13696998.2013.771641.
   PubMedGoogle Scholar
• Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ. 2013;16(2):231-239. doi: 10.3111/13696998.2012.751025.
   PubMedGoogle Scholar
• MacEwan JP, Kamat SA, Duffy RA, et al. Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics. Psychiatr Serv. 2016;67(11):1183-1188. doi: 10.1176/appi.ps.201500455.
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754-768. doi: 10.18553/jmcp.2015.21.9.754.
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Syst Pharm. 2015;72(5):378-389. doi: 10.2146/ajhp140219.
   PubMed Web of Science ®Google Scholar
• Lafeuille M-H, Laliberté-Auger F, Lefebvre P, et al. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013;13(1):221. doi: 10.1186/1471-244x-13-221.
   PubMed Web of Science ®Google Scholar
• Young-Xu Y, Duh MS, Muser E, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia. J Clin Psychiatry. 2016;77(10):e1332-e1341. doi: 10.4088/JCP.16m10745.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Muser E, Joshi K, et al. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia and comorbid substance abuse. Clin Ther. 2017;39(7):1380-1395.e4. doi: 10.1016/j.clinthera.2017.05.356.
   PubMed Web of Science ®Google Scholar
• Baser O, Xie L, Pesa J, et al. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ. 2015;18(5):357-365. doi: 10.3111/13696998.2014.1001514.
   PubMed Web of Science ®Google Scholar
• Pesa JA, Muser E, Montejano LB, et al. Costs and resource utilization among Medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Drugs Real World Outcomes. 2015;2(4):377-385. doi: 10.1007/s40801-015-0043-4.
   PubMedGoogle Scholar
• Pesa JA, Doshi D, Wang L, et al. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. Curr Med Res Opin. 2017;33(4):723-731. doi: 10.1080/03007995.2016.1278202.
   PubMed Web of Science ®Google Scholar
• Fayek M, Flowers C, Signorelli D, et al. Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiatr Serv. 2003;54(11):1453-1454, 1456. doi: 10.1176/appi.ps.54.11.1453. PubMed PMID: 14600298; eng.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Sanghani S, Russ MJ, et al. Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting. Int Clin Psychopharmacol. 2017;32(3):161-168. doi: 10.1097/yic.0000000000000165.
   PubMed Web of Science ®Google Scholar
• Hanssens L, De Hert M, Wampers M, et al. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin Pract Epidemiol Ment Health. 2006;2:11. doi: 10.1186/1745-0179-2-11.
   PubMedGoogle Scholar
• Castle D, Morgan V, Jablensky A. Antipsychotic use in Australia: the patients’ perspective. Aust N Z J Psychiatry. 2002;36(5):633-641. doi: 10.1046/j.1440-1614.2002.01037.x.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry. 2018;195(S52):s37-s42. doi: 10.1192/bjp.195.52.s37.
   Web of Science ®Google Scholar
• Samalin L, Garnier M, Auclair C, et al. Clinical decision-making in the treatment of schizophrenia: focus on long-acting injectable antipsychotics. Int J Mol Sci. 2016;17(11):1935. doi: 10.3390/ijms17111935. PubMed PMID: PMC5133930.
   Web of Science ®Google Scholar
• De Risio A, P Lang A. History and therapeutic rationale of long acting antipsychotics. Curr Clin Pharmacol. 2014;9(1):39-52.
   PubMedGoogle Scholar
• Sim K, Su A, Ungvari GS, et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol. 2004;19(2):103-109. doi: 10.1002/hup.571.
   PubMed Web of Science ®Google Scholar
• Nuhoho S, Saad A, Saumell G, et al. Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates. Curr Med Res Opin. 2018;34(4):601-611. doi: 10.1080/03007995.2017.1417246.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Maia-Lopes S, Goswami P, et al. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. J Med Econ. 2016;19(9):913-921. doi: 10.1080/13696998.2016.1184156.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Pudas H, Goswami P, et al. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. J Med Econ. 2016;19(2):111-120. doi: 10.3111/13696998.2015.1100115.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry. 2014;68(6):416-427. doi: 10.3109/08039488.2013.852243.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Vicente C, Zilbershtein R, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatr. 2013;25(2):85-94. doi: 10.1111/j.1601-5215.2012.00670.x.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Geitona M, Chaidemenos A, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry. 2012;11(1):18. doi: 10.1186/1744-859X-11-18.
   PubMed Web of Science ®Google Scholar
• Madden JM, Adams AS, LeCates RF, et al. Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D. JAMA Psychiatry. 2015;72(2):179-188.
   PubMed Web of Science ®Google Scholar
• Hemels M, Einarson TR, Zilbershtein R, et al. Cost-effectiveness of injectable atypical long-acting antipsychotics for chronic schizophrenia in Poland. Value Health. 2013;16(7):A548. doi: 10.1016/j.jval.2013.08.1406.
   Web of Science ®Google Scholar
• Lafeuille M-H, Gravel J, Lefebvre P, et al. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ. 2013;16(11):1290-1299.
   PubMedGoogle Scholar
• Si T, Li N, Lu H, et al. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: a post-hoc analysis of a one-year, open-label study stratified by medication adherence. J Psychopharmacol. 2018;32(6):691-701. doi: 10.1177/0269881118772449.
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health (NIMH). Schizophrenia [Internet] [cited 2017 Nov]. 2017. Available from: https://www.nimh.nih.gov/health/statistics/prevalence/file_148221.pdf
   Google Scholar
• Red Book Online Search – paliperidone palmitate [Internet]. Truven Health Analytics LLC; 2018 [cited 2018 Jan 21]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/CS/40062F/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/9F4E2D/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm = paliperidone%20palmitate&searchType = redbookGenericName&searchTermId = 929453&searchContent = REDBOOK&searchFilterAD = filterADActive&searchFilterRepackager = filterExcludeRepackager&searchPattern=%5Epaliper
   Google Scholar
• Centers for Medicare and Medicaid Services. Medicaid Drug Rebate Program 2017 [Internet] [cited 2018 Aug 27]. 2018. Available from: https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html
   Google Scholar
• Red Book Online Search [Internet]. Truven Health Analytics LLC; 2018 [cited 2018 Jan 21]. https://www.micromedexsolutions.com/micromedex2/librarian/ssl/true
   Google Scholar
• US Food and Drug Administration. Saphris (asenapine) Prescribing Information [Internet] [cited 2017 Feb]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s022lbl.pdf
   Google Scholar
• US Food and Drug Administration. Fanapt (iloperidone) Prescribing Information [Internet] [cited 2017 Feb]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022192s018s021lbl.pdf
   Google Scholar
• US Food and Drug Administration. Latuda (lurasidone hydrochloride) Prescribing Information [Internet] [cited 2017 Feb]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/200603s028lbl.pdf
   Google Scholar
• US Food and Drug Administration. Invega (paliperidone) Prescribing Information [Internet] [cited 2017 Aug]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021999s034lbl.pdf
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). Weighted national estimates from HCUP National (Nationwide) Inpatient Sample (NIS) [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2014 [cited 2018 Jan 23]. Available from: https://hcupnet.ahrq.gov/
   Google Scholar
• Healthcare Cost and Utilization Project (HCUP). Statistical brief #189: hospital readmissions involving psychiatric disorders, 2012 [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (ACRQ); 2015 [cited 2018 Jan 23]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb189-Hospital-Readmissions-Psychiatric-Disorders-2012.jsp
   Google Scholar
• Dilla T, Ciudad A, Álvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;7:275-284. doi: 10.2147/PPA.S41609.
   PubMed Web of Science ®Google Scholar